Meeting
2023 ASCO Genitourinary Cancers Symposium
Dynamic and immunocytochemistry analysis of circulation tumor cells (CTCs) in blood samples from patients with advanced ccRCC starting first-line treatment in a Brazilian Cancer Center.
Authors
Milena Shizue Tariki
AC Camargo Cancer Center, São Paulo, Brazil
Milena Shizue Tariki , Anna Paula Carreta Ruano , Jacqueline Aparecida Torres , Alexcia Camila Braun , Daniela JF Costa , Giovana Tardin Torrezan , Dirce Maria Carraro , Walter Henriques da Costa , Ludmilla T.D. Chinen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 704)
DOI
10.1200/JCO.2023.41.6_suppl.704
Abstract #
704
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).
First Author: Martin Henner Voss
Poster
2024 ASCO Genitourinary Cancers Symposium
The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.
First Author: Zilin Wang
Poster
2023 ASCO Annual Meeting
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
First Author: Nourhan El Ahmar
Poster
2023 ASCO Annual Meeting
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.
First Author: Itamar Sela